Press Release

HeartFlow Announces Appointment of Several Key Executive Hires

Broad Experience, Track Records of Success Position Company for Global Growth, Commercialization

REDWOOD CITY, Calif. – August 28, 2014 – HeartFlow, Inc. today announced the recent appointment of several key executives including Baird Radford, as chief financial officer; Brent Ness, as chief commercial officer; Robert Eno, as vice president of marketing; and Yoshiki Kawabata, as president of HeartFlow Japan GK.

“This team shares broad experience and significant track records of success in bringing to market some of our era’s most innovative technologies, across multiple fields and specialties. As a company, we share a vision of improving patient outcomes and experiences and reducing costs to the health care system,” said John H. Stevens, M.D., chairman and CEO of HeartFlow. “These individuals provide the exact experience and skills needed as we prepare to become a global, commercial stage company. I am thrilled to welcome Baird, Brent, Rob and Yoshiki to the HeartFlow family.”

Baird Radford has more than 20 years of public company finance experience in Silicon Valley. Prior to joining HeartFlow, Mr. Radford served as vice president of finance at Intuitive Surgical, Inc., with responsibility for financial planning and analysis, investor relations, and enterprise analytics. Prior to Intuitive Surgical, Mr. Radford held various positions at eBay, Inc., including vice president of finance for Marketplaces Europe, as well as vice president, corporate controller, and chief accounting officer. Mr. Radford also worked in the audit practice of PricewaterhouseCoopers LLP. He received his B.B.A. from Ohio University.

Brent Ness has more than 25 years of experience in commercial and executive roles in health care. Prior to joining HeartFlow Mr. Ness served as president and chief commercial officer of ProNerve LLC, a leader in the field of Intraoperative Neurophysiological Monitoring (IOM), and as vice president of global sales and marketing for Medtronic Navigation. Prior to Medtronic, Mr. Ness held the positions of vice president of sales operations North America for Philips and corporate director of corporate accounts for GE Healthcare. He earned an M.B.A. from the University of Colorado and a B.S. from the University of North Dakota.

Robert Eno has 20 years of experience in bringing disruptive medical technologies to market. Prior to joining HeartFlow, he held the position of vice president of marketing and international sales at OptiMedica, which was acquired by Abbott. Previously, he served as vice president of marketing at NeoGuide Systems (acquired by Intuitive Surgical) and as vice president of sales and marketing at Avantec Vascular (acquired by Goodman Co. Ltd). He also held several marketing and strategic planning positions at Guidant Corporation (acquired by Abbott). He received his M.B.A. degree from Stanford University’s Graduate School of Business and his A.B. from Stanford University, where he was Phi Beta Kappa.

Yoshiki Kawabata has more than 25 years of experience in a variety of medical device businesses including surgical staplers, endoscopic devices, electrophysiology ablation products, cardiac intervention catheters, fractional flow reserve and optical coherence tomography devices and in vitro diagnostics products. Prior to joining HeartFlow, he held the position of senior director of business development and alliances at Adachi, Co., Ltd. He has held multiple roles in sales, marketing, business development, R&D, and franchise management at St. Jude Medical, Johnson & Johnson, Baxter, and Century Medical in Japan. He received his B. S. degree in Law from Rikkyo University.

About HeartFlow, Inc.

Founded in 2007, HeartFlow, Inc., is a cardiovascular company based in Redwood City, Calif. A pioneer in the field of non-invasive coronary artery disease diagnosis, HeartFlow is committed to developing technology designed to help physicians noninvasively diagnose coronary artery disease and improve patient outcomes while reducing health care costs. For more information visit www.heartflow.com.


Contact Us

*Required fields

Request the HeartFlow Analysis Near You

If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.

*Required fields

残念ながら、GDPR 規制により、この Web フォームを通じて求人への応募やキャリアに関する問い合わせを受け付けることはできません。弊社を通じてお申込みください 採用ページ. ご関心をお寄せいただきありがとうございます!

オンライン提出フォームから研究助成金を申請してください。

HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用​​することを目的としています。

ハートフロー分析に関する追加の適応情報については、次のサイトをご覧ください。www.heartflow.com/indications.

さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.

The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.

For additional indication information about the HeartFlow Analysis, please visit www.heartflow.com/indications.

If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.

Please apply for research grants through our online submission form.

Unfortunately, we cannot take job applications or career inquiries through this web form due to GDPR regulations. Please apply through our Careers Page. Thank you for your interest!

Campbell Rogers, M.D., F.A.C.C.

Executive Vice President and Chief Medical Officer

Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.

He received his A.B. from Harvard College and his M.D. from Harvard Medical School.